In the UK, coverage depends on NHS commissioning rather than insurance, and NICE now recommends Wegovy within specialist services. Saxenda has more limited NHS use. In private healthcare or in other countries, coverage varies by insurer, but newer guidance tends to prioritise Wegovy because of its stronger results. The UK context: NHS commissioning, not insurance Unlike in the United States, where health insurance policies determine which drugs are covered, the UK relies on t

Wegovy works directly on appetite signals in the brain, helping people feel full sooner and think less about food. Other medicines act...

Wegovy has shown sustained weight loss of around 15% at 68 weeks, and many participants maintained benefits at two years. Qsymia (not...

Survey and trial follow-ups suggest people report higher satisfaction with Wegovy than older GLP-1 drugs, mainly because of greater...

Wegovy is taken once weekly via an injection pen, with doses stepped up over 16 weeks. Saxenda requires a daily injection, Mounjaro is a...

Phentermine can produce modest, short-term weight loss, but it is not licensed in the UK for obesity treatment. In contrast, semaglutide...

Since both contain semaglutide, their side-effect profiles are similar — most commonly nausea, vomiting, and diarrhoea. Wegovy uses a...

On the NHS, costs are set through commercial arrangements and are not always public, while in private practice the listed prices for...

In major STEP trials, Wegovy led to about 15% weight loss over 68 weeks. Contrave (called Mysimba in the UK) generally achieves around 6–9% across pivotal studies. This means semaglutide tends to provide greater weight reduction than naltrexone/bupropion combinations. Two very different approaches Although both Wegovy and Contrave are prescribed for weight management, they work in completely different ways. Wegovy contains semaglutide, a GLP-1 receptor agonist that reduces ap

In a head-to-head trial published in The New England Journal of Medicine , people taking Wegovy lost on average about 15.8% of their body weight over 68 weeks compared with 6.4% for those on Saxenda (liraglutide). This makes Wegovy the more effective of the two for weight loss in most cases. Two GLP-1 medicines, one key difference Both Wegovy and Saxenda belong to the same class of medicines, known as GLP-1 receptor agonists. They work by mimicking a natural hormone that redu

Wegovy contains semaglutide at a higher dose and is licensed for weight management, while Trulicity (dulaglutide) is prescribed for type 2 diabetes. Weight changes with dulaglutide are usually modest compared with the significant reductions seen in trials of semaglutide for obesity. Two GLP-1 medicines, two purposes Both Wegovy and Trulicity belong to the same broad group of medicines known as GLP-1 receptor agonists. They mimic a natural hormone in the body that helps reduce

They’re not the same product: both contain semaglutide, but Wegovy is the weight-management brand (higher dose) and Ozempic is the type-2-diabetes brand (lower dose ranges). Indications, dosing schedules, and pens differ, so switching should be guided by a prescriber. Same ingredient, different goals It’s true that both Wegovy and Ozempic are based on semaglutide, a GLP-1 receptor agonist that helps regulate appetite, digestion, and blood sugar. But they were developed for di

For weight management, Wegovy (semaglutide 2.4 mg weekly) is the licensed option and generally achieves greater weight loss than the...

Choosing between Wegovy and Mounjaro comes down to what you’re aiming for (weight, blood sugar, side-effect profile) and what’s available to you. Many people see strong results with both; tirzepatide can yield greater reductions for some, while semaglutide has a longer real-world track record. Why these two drugs stand out Wegovy and Mounjaro are often compared because they’re part of the same family of treatments known as incretin-based medicines. Both act on hormones that h

Wegovy contains semaglutide, a GLP-1 receptor agonist used at higher weekly doses for weight management. It helps reduce appetite and supports lower energy intake alongside everyday habits like balanced eating and movement. What semaglutide actually is Semaglutide is a medicine that mimics GLP-1 (glucagon-like peptide-1), a natural hormone in the body. GLP-1 plays a key role in appetite and metabolism: it slows the emptying of the stomach, enhances the release of insulin when

Wegovy and Ozempic share the same active ingredient (semaglutide), but they’re licensed for different uses and doses — Wegovy for weight...

Mounjaro (tirzepatide) and Wegovy (semaglutide) are both effective; some studies show larger average weight loss with tirzepatide, but individual response, side-effects, access, and clinical goals matter. The “better” choice is the one that fits your health needs and tolerability after a clinician review. Two medicines, two mechanisms Wegovy and Mounjaro both belong to a family of medicines that mimic natural gut hormones involved in appetite and metabolism. Wegovy contains s

Yes — both men and women can use Wegovy when they meet eligibility criteria. Because exposure in pregnancy isn’t recommended, women of child-bearing potential are advised to use effective contraception and to discuss stopping in advance if planning a pregnancy. If you become pregnant, contact your clinical team promptly to review treatment. Apart from pregnancy and breastfeeding considerations, the approach to dosing and monitoring is similar across genders. Equal access in e

In UK services, routine age use focuses on adults within specialist pathways. Use in people under 18 is specialist and not part of standard adult commissioning routes. If a young person is being considered for treatment, this would happen in paediatric services with multidisciplinary input and careful assessment of risks and benefits. Focus on adults in UK guidance In the UK, Wegovy is commissioned primarily for adults who meet strict eligibility criteria. NICE guidance and c

Suitability depends on your health profile, but many people with common conditions like type 2 diabetes or high blood pressure can use Wegovy within specialist care. If you take insulin or medicines that can cause low blood sugar, your prescriber may adjust doses to reduce hypo risk as appetite changes. Blood-pressure tablets usually continue as normal, with routine monitoring as weight and salt intake shift. People with a history of certain rare endocrine or pancreatic issue